Indeed, a number of HSP90 inhibitors such as AUY922 that do not significantly affect normal cell survival are currently in clinical studies for the treatment of various types of cancers including wild-type KRAS colon cancer [14–16]. This evidence concerns the gene KRAS and malignant colon neoplasm.